Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 6, 1997

View Archived Issues

Ethical Holdings: FY 1997 highlights

Andrx: Q3 and nine-month highlights

Enzo Biochem: Q4 1997 highlights

Biovail: Q3 and nine-month highlights

Transkaryotic Therapies: Q3 1997 highlights

CellPro: Q2 1997 highlights

InSite Vision: Q3 1997 highlights

First market introduction for dolasetron

Zeneca selects new HLE inhibitor for clinical development

Antihypertensive and antianginal efficacy of mibefradil confirmed in clinical trials

Intercardia to acquire Transcell

Phase I trials begin on TNT in glioma patients

FDA approves generic formulation of oxycodone/acetaminophen

Genetronics cleared to proceed with electroporation trial in France

Safety of nemorubicin (daily x 3 every 28 days) evaluated in phase I trial

Patient enrollment complete for phase II trial of memantine

Neuropeptide Y5 receptor emerges as an important new target in obesity

U.S. clinical stroke trial supports efficacy and safety of citicoline

Melatonin evaluated for bipolar disorder

Receptagen and Scitech Genetics approach merger

NIH scientists identify nicotinic receptor in hippocampus

NIAID awards Progenics funds for HIV program

Cellegy to acquire nitroglycerin-based product for anorectal conditions

Heat shock proteins: a new vaccine strategy

New proton pump inhibitors from Apotex

LG Chemical reports new compounds for AIDS

New neuroprotectants from HHS

U.S. patent issued for Cambridge NeuroScience's drug delivery system

TNF/PDE inhibitors disclosed by Rhone-Poulenc Rorer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 29, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...